AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of earliest event reported): July 16, 2020
name of registrant as specified in charter)|
|(State or other jurisdiction
Prospect Street, Suite 525, La Jolla, CA 92037
of Principal Executive Offices) (Zip Code)
Telephone Number, Including Area Code)
Name or Former Address, If Changed Since Last Report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
growth company ☒
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on which registered|
Stock, par value $0.001 per share
NASDAQ Stock Market LLC|
||Entry Into a Material Definitive Agreement|
On July 16, 2020, INmune Bio, Inc.
(the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC,
as representative of the underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the
Company agreed to issue and sell an aggregate of 2,173,914 shares of its common stock, par value $0.001 per share (the “Shares”),
to the Underwriters (the “Offering”). The public offering price is $10.00 per Share, and the Underwriters have agreed
to purchase the Shares pursuant to the Underwriting Agreement at a price of $9.40 per Share. Pursuant to the Underwriting Agreement,
the Company also granted the Underwriters an over-allotment option to purchase up to an additional 326,086 shares of its common
The Company estimates that net proceeds
from the Offering will be approximately $20 million, after deducting underwriting discounts and commissions and estimated Offering
expenses payable by the Company, and assuming no exercise of the Underwriters’ over-allotment option. The Company expects
to use the net proceeds from the Offering for general corporate purposes, including to support research and development, including
clinical trials. The Offering is expected to close on July 20, 2020, subject to the satisfaction of customary closing conditions.
Underwriting Agreement contains customary representations, warranties and agreements by the Company, conditions to closing, termination
provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The foregoing
description of the Underwriting Agreement is qualified in its entirety by reference to such Underwriting Agreement, which is filed
as Exhibit 1.1 hereto and is incorporated herein by reference.
The Offering is being made pursuant to the Company’s shelf
registration statement on Form S-3 (File No. 333-237368) that was filed with the Securities and Exchange Commission (the “SEC”)
on March 24, 2020 and became effective on April 2, 2020 (the “Registration Statement”). The Offering is being made
only by means of a prospectus supplement and accompanying base prospectus that form part of the Registration Statement. A preliminary
prospectus supplement, dated July 15, 2020, together with the accompanying prospectus dated April 2, 2020, relating to and describing
the terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus
supplement and accompanying base prospectus will be filed with the SEC and, when so filed, will also be available on the SEC’s
website set forth above.
A copy of the opinion of Sichenzia
Ross Ference LLP, relating to the validity of the Shares in connection with the Offering, is filed with this Current Report on
Form 8-K as Exhibit 5.1.
Item 8.01. Other
July 16, 2020, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
9.01 Financial statements and Exhibits
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|Date: July 16, 2020